| A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects S Talukdar, Y Zhou, D Li, M Rossulek, J Dong, V Somayaji, Y Weng, ... Cell metabolism 23 (3), 427-440, 2016 | 511 | 2016 |
| Physiology and pathophysiology of insulin secretion H Rasmussen, KC Zawalich, S Ganesan, R Calle, WS Zawalich Diabetes Care 13 (6), 655-666, 1990 | 186 | 1990 |
| Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp (a) HA Deshmukh, HM Colhoun, T Johnson, PM McKeigue, DJ Betteridge, ... Journal of lipid research 53 (5), 1000-1011, 2012 | 154 | 2012 |
| Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese … AM Kim, VR Somayaji, JQ Dong, TP Rolph, Y Weng, JR Chabot, ... Diabetes, Obesity and Metabolism 19 (12), 1762-1772, 2017 | 146 | 2017 |
| A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts N Van Leeuwen, G Nijpels, ML Becker, H Deshmukh, K Zhou, ... Diabetologia 55 (7), 1971-1977, 2012 | 142 | 2012 |
| Diacylglycerol Production, Ca2+ Influx, and Protein Kinase C Activation in Sustained Cellular Responses H Rasmussen, CM Isales, R Calle, D Throckmorton, M Anderson, ... Endocrine Reviews 16 (5), 649-681, 1995 | 141 | 1995 |
| ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials RA Calle, NB Amin, S Carvajal-Gonzalez, TT Ross, A Bergman, ... Nature Medicine 27 (10), 1836-1848, 2021 | 139 | 2021 |
| In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET MD Normandin, KF Petersen, YS Ding, SF Lin, S Naik, K Fowles, ... Journal of nuclear medicine 53 (6), 908-916, 2012 | 129 | 2012 |
| Glucose-induced translocation of protein kinase C in rat pancreatic islets S Ganesan, R Calle, K Zawalich, JI Smallwood, WS Zawalich, ... Proceedings of the National Academy of Sciences 87 (24), 9893-9897, 1990 | 124 | 1990 |
| Pharmacokinetics and pharmacodynamics of PF‐05231023, a novel long‐acting FGF21 mimetic, in a first‐in‐human study JQ Dong, M Rossulek, VR Somayaji, D Baltrukonis, Y Liang, K Hudson, ... British journal of clinical pharmacology 80 (5), 1051-1063, 2015 | 117 | 2015 |
| Modulation of 11β-hydroxysteroid dehydrogenase (11βHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11βHSD1 inhibitor R Courtney, PM Stewart, M Toh, MN Ndongo, RA Calle, B Hirshberg The Journal of Clinical Endocrinology & Metabolism 93 (2), 550-556, 2008 | 110 | 2008 |
| GDF-15 neutralization alleviates platinum-based chemotherapy-induced emesis, anorexia, and weight loss in mice and nonhuman primates DM Breen, H Kim, D Bennett, RA Calle, S Collins, RM Esquejo, T He, ... Cell Metabolism 32 (6), 938-950. e6, 2020 | 107 | 2020 |
| Immunocytochemical localization of alpha-protein kinase C in rat pancreatic beta-cells during glucose-induced insulin secretion. S Ganesan, R Calle, K Zawalich, K Greenawalt, W Zawalich, GI Shulman, ... The Journal of cell biology 119 (2), 313-324, 1992 | 94 | 1992 |
| Glucose-induced phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in isolated rat pancreatic islets. R Calle, S Ganesan, JI Smallwood, H Rasmussen Journal of Biological Chemistry 267 (26), 18723-18727, 1992 | 86 | 1992 |
| Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin … Y Weng, JR Chabot, B Bernardo, Q Yan, Y Zhu, MB Brenner, C Vage, ... PloS one 10 (3), e0119104, 2015 | 73 | 2015 |
| Standardized mixed-meal tolerance and arginine stimulation tests provide reproducible and complementary measures of β-cell function: results from the foundation for the … SS Shankar, A Vella, RH Raymond, MA Staten, RA Calle, RN Bergman, ... Diabetes care 39 (9), 1602-1613, 2016 | 68 | 2016 |
| FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance B Bernardo, M Lu, G Bandyopadhyay, P Li, Y Zhou, J Huang, N Levin, ... Scientific reports 5 (1), 11382, 2015 | 61 | 2015 |
| Two dose‐ranging studies with PF‐04937319, a systemic partial activator of glucokinase, as add‐on therapy to metformin in adults with type 2 diabetes NB Amin, N Aggarwal, D Pall, G Paragh, WS Denney, V Le, M Riggs, ... Diabetes, Obesity and Metabolism 17 (8), 751-759, 2015 | 53 | 2015 |
| Differential effects of agonists of aldosterone secretion on steroidogenic acute regulatory phosphorylation S Betancourt-Calle, RA Calle, CM Isales, S White, H Rasmussen, ... Molecular and cellular endocrinology 173 (1-2), 87-94, 2001 | 49 | 2001 |
| Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial DJ Kazierad, K Chidsey, VR Somayaji, AJ Bergman, MJ Birnbaum, ... Med 2 (7), 800-813. e3, 2021 | 48 | 2021 |
Shridar GanesanProfessor of Medicine, Rutgers Cancer Institute of New Jersey在 cinj.rutgers.edu 的电子邮件经过验证
